Abstract
AbstractOral administration of N,N-Dimethylglycine (DMG), a tertiary amino acid, presumably enhances oxygen utilization by tissue and complex with free radicals. Beneficial effects are improved endurance performance and reduction fatigue in humans and animals. This pilot study reports the results over a one-year double-blind, placebo-controlled trial of DMG in 30 randomized patients with progressive multiple sclerosis. No treatment effects were found between the placebo group and the DMG group for disability, fatigue, cognitive, or gait parameters.
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Tonda, M. E., & Hart, L. L. (1992). N,N dimethylglycine and L-carnitine as performance enhancers in athletes, Ann Pharmacother, 26(7-8), 935–937.
2. Gray, M., & Titlow, L. (1982). B15- myth or miracle? The Physician Sports Medicine, 10(1), 107–112. https://doi.org/10.1080/00913847.1982.11947150.
3. Tebecis, A. K., & Di Maria, A. (1972). Strychnine-sensitive inhibition in the medullary reticular formation: Evidence for glycine as an inhibitory transmitter. Brain Research, 40(2), 373–383. https://doi.org/10.1016/0006-8993(72)90140-0.
4. Mathews, C. K., & van Holde, K. E. (1990). Biochemistry. Benjamin/Cummings.
5. Parks, N. E., Jackson-Tarlton, C. S., Vacchi, L., Merdad, R., & Johnston, B. C. (2020). Dietary interventions for multiple sclerosis-related outcomes. Cochrane Database of Systematic Reviews, 5, CD004192. https://doi.org/10.1002/14651858.CD004192.pub4.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献